{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:28:58Z","timestamp":1794644938228,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77358-7","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:02:33Z","timestamp":1791536553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The conformation-selective PI3K\u03b4 inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-2158","authenticated-orcid":false,"given":"Anna Maria","family":"Di Giacomo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Simonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Losurdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-6319","authenticated-orcid":false,"given":"Pavlina","family":"Spiliopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-377X","authenticated-orcid":false,"given":"Vincenzo","family":"D\u2019Alonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7255-362X","authenticated-orcid":false,"given":"Hugo","family":"Barcenilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7256-5770","authenticated-orcid":false,"given":"Tadepally","family":"Lakshmikanth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8103-0046","authenticated-orcid":false,"given":"Petter","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1377-7308","authenticated-orcid":false,"given":"Michael","family":"Lahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1353-5867","authenticated-orcid":false,"given":"Giusy","family":"Di Conza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Zorrilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-0081","authenticated-orcid":false,"given":"Lars","family":"van der Veen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-4362","authenticated-orcid":false,"given":"Alessio","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paramjit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3059-3652","authenticated-orcid":false,"given":"Tracey","family":"Hammett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Durini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3954-303X","authenticated-orcid":false,"given":"Andrea","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Sindhwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariaelena","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Snijder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayad","family":"Abdul-Ahad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-1119","authenticated-orcid":false,"given":"Aniko","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Postiglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Hopton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9120-5332","authenticated-orcid":false,"given":"Vincent","family":"Vuaroqueaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Lise","family":"Peille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-8662","authenticated-orcid":false,"given":"Ming","family":"Poi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9531-0970","authenticated-orcid":false,"given":"David","family":"Spetzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5201-885X","authenticated-orcid":false,"given":"Thomas R. Jeffry","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-6321","authenticated-orcid":false,"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"77358_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","volume":"20","author":"B Vanhaesebroeck","year":"2021","unstructured":"Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., Andre, F. & Okkenhaug, K. PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov. 20, 741\u2013769 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"77358_CR2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655\u20131657 (2002).","journal-title":"Science"},{"key":"77358_CR3","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","volume":"94","author":"B Vanhaesebroeck","year":"1997","unstructured":"Vanhaesebroeck, B. et al. p110\u03b4, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. USA 94, 4330\u20134335 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77358_CR4","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S1470-2045(22)00300-X","volume":"23","author":"JR Brown","year":"2022","unstructured":"Brown, J. R., Danilov, A. V., LaCasce, A. S. & Davids, M. S. PI3K inhibitors in haematological malignancies. Lancet Oncol. 23, e364 (2022).","journal-title":"Lancet Oncol."},{"key":"77358_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0717-4","volume":"9","author":"E Goulielmaki","year":"2018","unstructured":"Goulielmaki, E. et al. Pharmacological inactivation of the PI3K p110\u03b4 prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death Dis. 9, 678 (2018).","journal-title":"Cell Death Dis."},{"key":"77358_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri1056","volume":"3","author":"K Okkenhaug","year":"2003","unstructured":"Okkenhaug, K. & Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3, 317\u2013330 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"77358_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature13444","volume":"510","author":"K Ali","year":"2014","unstructured":"Ali, K. et al. Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407\u2013411 (2014).","journal-title":"Nature"},{"key":"77358_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1042\/BJ20112214","volume":"443","author":"MA Whitehead","year":"2012","unstructured":"Whitehead, M. A., Bombardieri, M., Pitzalis, C. & Vanhaesebroeck, B. Isoform-selective induction of human p110\u03b4 PI3K expression by TNF\u03b1: identification of a new and inducible PIK3CD promoter. Biochem. J. 443, 857\u2013867 (2012).","journal-title":"Biochem. J."},{"key":"77358_CR9","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-16-1839","volume":"77","author":"S Ahmad","year":"2017","unstructured":"Ahmad, S. et al. Differential PI3K\u03b4 signaling in CD4+ T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Cancer Res. 77, 1892\u20131904 (2017).","journal-title":"Cancer Res."},{"key":"77358_CR10","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.18632\/oncotarget.12742","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Wan, W. Z., Li, Y., Zhou, G. L. & Liu, X. G. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents. Oncotarget 8, 7181\u20137200 (2017).","journal-title":"Oncotarget"},{"key":"77358_CR11","doi-asserted-by":"crossref","unstructured":"Conduit, S. E., Vasan, N., Brown, J. R., Perry, M. W. D. & Vanhaesebroeck, B. A renaissance in targeting the PI3K\/AKT\/mTOR pathway. Nat. Rev. Drug Discov. 25, 469\u2013493 (2026).","DOI":"10.1038\/s41573-026-01388-5"},{"key":"77358_CR12","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.bcp.2008.12.022","volume":"77","author":"LO Kirkland","year":"2009","unstructured":"Kirkland, L. O. & McInnes, C. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem. Pharm. 77, 1561\u20131571 (2009).","journal-title":"Biochem. Pharm."},{"key":"77358_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1158\/2767-9764.CRC-22-0477","volume":"3","author":"Z Johnson","year":"2023","unstructured":"Johnson, Z. et al. IOA-244 is a non-ATP-competitive, highly selective, tolerable PI3K delta inhibitor that targets solid tumors and breaks immune tolerance. Cancer Res. Commun. 3, 576\u2013591 (2023).","journal-title":"Cancer Res. Commun."},{"key":"77358_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fimmu.2014.00233","volume":"5","author":"P Haselmayer","year":"2014","unstructured":"Haselmayer, P. et al. Characterization of novel PI3K\u03b4 inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies. Front. Immunol. 5, 233 (2014).","journal-title":"Front. Immunol."},{"key":"77358_CR15","doi-asserted-by":"publisher","unstructured":"Vadas, O. et al. PI3K\u03b4 is selectively inhibited by roginolisib through stabilizing of the C-terminal helix k\u03b112. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-026-77424-0 (2026).","DOI":"10.1038\/s41467-026-77424-0"},{"key":"77358_CR16","doi-asserted-by":"crossref","unstructured":"Solli, E. et al. The PI3K\u03b4 inhibitor roginolisib (IOA-244) preserves T-cell function and activity. Mol. Oncol. 20, 1612\u20131625 (2026).","DOI":"10.1002\/1878-0261.70203"},{"key":"77358_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101857","volume":"43","author":"C Kalla","year":"2024","unstructured":"Kalla, C. et al. The highly selective and oral phosphoinositide 3-kinase delta (PI3K-\u03b4) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition. Transl. Oncol. 43, 101857 (2024).","journal-title":"Transl. Oncol."},{"key":"77358_CR18","doi-asserted-by":"crossref","unstructured":"Sasi, B. K. et al. Novel PI3k\u03b4 inhibitor roginolisib synergizes with venetoclax in hematologic malignancies. Haematologica 110, 2974\u20132985 (2025).","DOI":"10.3324\/haematol.2024.287180"},{"key":"77358_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14256-1","volume":"11","author":"MA Durante","year":"2020","unstructured":"Durante, M. A. et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat. Commun. 11, 496 (2020).","journal-title":"Nat. Commun."},{"key":"77358_CR20","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.clinthera.2018.09.006","volume":"40","author":"O Moreno","year":"2018","unstructured":"Moreno, O. et al. Safety, pharmacokinetics, and pharmacodynamics of ME-401, an oral, potent, and selective inhibitor of phosphatidylinositol 3-kinase P110\u03b4, following single ascending dose administration to healthy volunteers. Clin. Ther. 40, 1855\u20131867 (2018).","journal-title":"Clin. Ther."},{"key":"77358_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/0974-620X.116652","volume":"6","author":"PL Mellen","year":"2013","unstructured":"Mellen, P. L., Morton, S. J. & Shields, C. L. American Joint Committee on Cancer staging of uveal melanoma. Oman J. Ophthalmol. 6, 116\u2013118 (2013).","journal-title":"Oman J. Ophthalmol."},{"key":"77358_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/10915818231200419","volume":"42","author":"L van der Veen","year":"2023","unstructured":"van der Veen, L., Schmitt, M., Deken, M. A. & Lahn, M. Non-clinical toxicology evaluation of the novel non-ATP competitive oral PI3 kinase delta inhibitor roginolisib. Int. J. Toxicol. 42, 515\u2013534 (2023).","journal-title":"Int. J. Toxicol."},{"key":"77358_CR23","doi-asserted-by":"crossref","unstructured":"Di Giacomo, A. M. et al. First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3K\u03b4) inhibitor IOA-244 in patients with advanced cancer: safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results. J. Clin. Oncol. 40, 3107 (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.3107"},{"key":"77358_CR24","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1111\/all.14747","volume":"76","author":"AF Santos","year":"2021","unstructured":"Santos, A. F., Alpan, O. & Hoffmann, H. J. Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. Allergy 76, 2420\u20132432 (2021).","journal-title":"Allergy"},{"key":"77358_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao, V. K. et al. A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood 141, 971\u2013983 (2023).","journal-title":"Blood"},{"key":"77358_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg, A. et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295, 328\u2013338 (2020).","journal-title":"Radiology"},{"key":"77358_CR27","doi-asserted-by":"crossref","unstructured":"Grossmann, P. et al. Defining the biological basis of radiomic phenotypes in lung cancer. Elife 6, e23421 (2017).","DOI":"10.7554\/eLife.23421"},{"key":"77358_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2022.12.001","volume":"56","author":"A Chow","year":"2023","unstructured":"Chow, A. et al. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity 56, 93\u2013106.e106 (2023).","journal-title":"Immunity"},{"key":"77358_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.18053","volume":"197","author":"D Gadi","year":"2022","unstructured":"Gadi, D. et al. Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia. Br. J. Haematol. 197, 207\u2013211 (2022).","journal-title":"Br. J. Haematol."},{"key":"77358_CR30","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1084\/jem.20170277","volume":"216","author":"M Rapp","year":"2019","unstructured":"Rapp, M. et al. CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. J. Exp. Med. 216, 1170\u20131181 (2019).","journal-title":"J. Exp. Med."},{"key":"77358_CR31","first-page":"1324","volume":"17","author":"S Landreville","year":"2011","unstructured":"Landreville, S. et al. Identification of differentially expressed genes in uveal melanoma using suppressive subtractive hybridization. Mol. Vis. 17, 1324\u20131333 (2011).","journal-title":"Mol. Vis."},{"key":"77358_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","volume":"2","author":"P Castel","year":"2021","unstructured":"Castel, P., Toska, E., Engelman, J. A. & Scaltriti, M. The present and future of PI3K inhibitors for cancer therapy. Nat. Cancer 2, 587\u2013597 (2021).","journal-title":"Nat. Cancer"},{"key":"77358_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/nature02991","volume":"431","author":"K Ali","year":"2004","unstructured":"Ali, K. et al. Essential role for the p110\u03b4 phosphoinositide 3-kinase in the allergic response. Nature 431, 1007\u20131011 (2004).","journal-title":"Nature"},{"key":"77358_CR34","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-24-0967","volume":"30","author":"SS Skanland","year":"2024","unstructured":"Skanland, S. S., Okkenhaug, K. & Davids, M. S. PI3K inhibitors in hematology: when one door closes. Clin. Cancer Res. 30, 3667\u20133675 (2024).","journal-title":"Clin. Cancer Res."},{"key":"77358_CR35","doi-asserted-by":"publisher","first-page":"e1604","DOI":"10.1634\/theoncologist.2020-0321","volume":"25","author":"E Borazanci","year":"2020","unstructured":"Borazanci, E. et al. A phase Ib study of single-agent idelalisib followed by idelalisib in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Oncologist 25, e1604\u2013e1613 (2020).","journal-title":"Oncologist"},{"key":"77358_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","volume":"605","author":"S Eschweiler","year":"2022","unstructured":"Eschweiler, S. et al. Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs. Nature 605, 741\u2013746 (2022).","journal-title":"Nature"},{"key":"77358_CR37","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1158\/2767-9764.CRC-22-0461","volume":"3","author":"P Munster","year":"2023","unstructured":"Munster, P. et al. Combination of itacitinib or parsaclisib with pembrolizumab in patients with advanced solid tumors: a phase I study. Cancer Res. Commun. 3, 2572\u20132584 (2023).","journal-title":"Cancer Res. Commun."},{"key":"77358_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.it.2008.07.004","volume":"29","author":"M-S Kim","year":"2008","unstructured":"Kim, M.-S., R\u00e5dinger, M. & Gilfillan, A. M. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol. 29, 493\u2013501 (2008).","journal-title":"Trends Immunol."},{"key":"77358_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11523-019-00668-y","volume":"14","author":"O Moreno","year":"2019","unstructured":"Moreno, O. & Wood, J. Absorption, distribution, and binding profile of ME-401, a potent and selective oral small-molecule inhibitor of phosphatidylinositol 3-kinase delta (PI3K\u03b4) in animal and B-cell lymphoma models. Target Oncol. 14, 603\u2013611 (2019).","journal-title":"Target Oncol."},{"key":"77358_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00280-013-2208-8","volume":"72","author":"N Terranova","year":"2013","unstructured":"Terranova, N., Germani, M., Del Bene, F. & Magni, P. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination. Cancer Chemother. Pharm. 72, 471\u2013482 (2013).","journal-title":"Cancer Chemother. Pharm."},{"key":"77358_CR41","doi-asserted-by":"crossref","unstructured":"Gadkar, K. et al. Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors. CPT Pharmacometrics Syst. Pharmacol. 11, 616\u2013627 (2021).","DOI":"10.1002\/psp4.12749"},{"key":"77358_CR42","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/hematology.2020000119","volume":"2020","author":"A Hanlon","year":"2020","unstructured":"Hanlon, A. & Brander, D. M. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematol. Am. Soc. Hematol. Educ. Program 2020, 346\u2013356 (2020).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"77358_CR43","doi-asserted-by":"crossref","unstructured":"Kulbay, M. et al. Uveal melanoma: comprehensive review of its pathophysiology, diagnosis, treatment, and future perspectives. Biomedicines 12, 1758 (2024).","DOI":"10.3390\/biomedicines12081758"},{"key":"77358_CR44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/acs.chemrestox.8b00023","volume":"31","author":"J Zhu","year":"2018","unstructured":"Zhu, J. et al. Identification of novel pathways in idelalisib metabolism and bioactivation. Chem. Res. Toxicol. 31, 548\u2013555 (2018).","journal-title":"Chem. Res. Toxicol."},{"key":"77358_CR45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1021\/acs.chemrestox.6b00357","volume":"30","author":"T Cho","year":"2017","unstructured":"Cho, T. & Uetrecht, J. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction. Chem. Res. Toxicol. 30, 295\u2013314 (2017).","journal-title":"Chem. Res. Toxicol."},{"key":"77358_CR46","doi-asserted-by":"crossref","unstructured":"Shoushtari, A. N. et al. A phase Ib study of sotrastaurin, a PKC inhibitor, and alpelisib, a PI3Kalpha inhibitor, in patients with metastatic uveal melanoma. Cancers 13, 5504 (2021).","DOI":"10.3390\/cancers13215504"},{"key":"77358_CR47","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med."},{"key":"77358_CR48","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","volume":"28","author":"RD Carvajal","year":"2022","unstructured":"Carvajal, R. D. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat. Med. 28, 2364\u20132373 (2022).","journal-title":"Nat. Med."},{"key":"77358_CR49","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala, E. S., Hernberg, M. & Kivela, T. T. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 29, 561\u2013568 (2019).","journal-title":"Melanoma Res."},{"key":"77358_CR50","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2214\/AJR.22.28229","volume":"220","author":"S Ahlawat","year":"2022","unstructured":"Ahlawat, S. et al. Clinical applications and controversies of whole-body MRI: AJR Expert Panel Narrative Review. AJR Am. J. Roentgenol. 220, 463\u2013475 (2022).","journal-title":"AJR Am. J. Roentgenol."},{"key":"77358_CR51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"77358_CR52","doi-asserted-by":"crossref","unstructured":"Galland, L. et al. Splenic volume as a surrogate marker of immune checkpoint inhibitor efficacy in metastatic non small cell lung cancer. Cancers 13, 3020 (2021).","DOI":"10.3390\/cancers13123020"},{"key":"77358_CR53","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41423-020-0490-z","volume":"17","author":"TE Taher","year":"2020","unstructured":"Taher, T. E. et al. CD5 and B lymphocyte responses: multifaceted effects through multitudes of pathways and channels. Cell Mol. Immunol. 17, 1201\u20131203 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"77358_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40933-8","volume":"9","author":"K de Jonge","year":"2019","unstructured":"de Jonge, K. et al. Circulating CD56bright NK cells inversely correlate with survival of melanoma patients. Sci. Rep. 9, 4487 (2019).","journal-title":"Sci. Rep."},{"key":"77358_CR55","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.celrep.2016.07.075","volume":"16","author":"R Saddawi-Konefka","year":"2016","unstructured":"Saddawi-Konefka, R. et al. Nrf2 induces IL-17D to mediate tumor and virus surveillance. Cell Rep. 16, 2348\u20132358 (2016).","journal-title":"Cell Rep."},{"key":"77358_CR56","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1159\/000508255","volume":"181","author":"X Liu","year":"2020","unstructured":"Liu, X., Sun, S. & Liu, D. IL-17D: a less studied cytokine of IL-17 family. Int. Arch. Allergy Immunol. 181, 618\u2013623 (2020).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"77358_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14290-4","volume":"11","author":"JB Williams","year":"2020","unstructured":"Williams, J. B. et al. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-gamma-signaling mutant cancer cells. Nat. Commun. 11, 602 (2020).","journal-title":"Nat. Commun."},{"key":"77358_CR58","doi-asserted-by":"crossref","unstructured":"Pedersen, J. G. et al. Increased soluble PD-1 predicts response to nivolumab plus ipilimumab in melanoma. Cancers 14, 3342 (2022).","DOI":"10.3390\/cancers14143342"},{"key":"77358_CR59","doi-asserted-by":"crossref","unstructured":"Hayashi, H. et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J. Clin. Invest. 134, e168318 (2024).","DOI":"10.1172\/JCI168318"},{"key":"77358_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53145-0","volume":"15","author":"M Rodrigues","year":"2024","unstructured":"Rodrigues, M. et al. Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp. Nat. Commun. 15, 8851 (2024).","journal-title":"Nat. Commun."},{"key":"77358_CR61","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrc3521","volume":"13","author":"M O\u2019Hayre","year":"2013","unstructured":"O\u2019Hayre, M. et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat. Rev. Cancer 13, 412\u2013424 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"77358_CR62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/CMR.0000000000000455","volume":"28","author":"PA Ascierto","year":"2018","unstructured":"Ascierto, P. A. et al. The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. Melanoma Res. 28, 333\u2013340 (2018).","journal-title":"Melanoma Res."},{"key":"77358_CR63","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1172\/JCI35636","volume":"118","author":"H Skvara","year":"2008","unstructured":"Skvara, H. et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J. Clin. Invest. 118, 3151\u20133159 (2008).","journal-title":"J. Clin. Invest."},{"key":"77358_CR64","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/1535-7163.MCT-13-0550","volume":"13","author":"E Musi","year":"2014","unstructured":"Musi, E., Ambrosini, G., de Stanchina, E. & Schwartz, G. K. The phosphoinositide 3-kinase alpha selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ\/GNA11-mutant uveal melanoma cells. Mol. Cancer Ther. 13, 1044\u20131053 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"77358_CR65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","volume":"19","author":"JA Beaver","year":"2018","unstructured":"Beaver, J. A. et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 19, 229\u2013239 (2018).","journal-title":"Lancet Oncol."},{"key":"77358_CR66","unstructured":"QIBA CT Volumetry Biomarker Committee. CT Tumor Volume Change for Advanced Disease, Clinically Feasible Profile. Version: Stage 3: Clinically Feasible, https:\/\/qibawiki.rsna.org\/index.php\/CT_Tumor_Volume_Change_for_Advanced_Disease,_Clinically_Feasible_Profile (2022)."},{"key":"77358_CR67","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/cncr.11113","volume":"97","author":"S Eskelin","year":"2003","unstructured":"Eskelin, S., Pyrhonen, S., Hahka-Kemppinen, M., Tuomaala, S. & Kivela, T. A prognostic model and staging for metastatic uveal melanoma. Cancer 97, 465\u2013475 (2003).","journal-title":"Cancer"},{"key":"77358_CR68","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin, P. et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur. J. Cancer 48, 441\u2013446 (2012).","journal-title":"Eur. J. Cancer"},{"key":"77358_CR69","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/j.acra.2020.03.004","volume":"28","author":"YS Velichko","year":"2021","unstructured":"Velichko, Y. S. et al. Association between the size and 3D CT-based radiomic features of breast cancer hepatic metastasis. Acad. Radiol. 28, e93\u2013e100 (2021).","journal-title":"Acad. Radiol."},{"key":"77358_CR70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-4939-8979-9_3","volume":"1913","author":"T Lakshmikanth","year":"2019","unstructured":"Lakshmikanth, T. & Brodin, P. Systems-level immune monitoring by mass cytometry. Methods Mol. Biol. 1913, 33\u201348 (2019).","journal-title":"Methods Mol. Biol."},{"key":"77358_CR71","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.cell.2024.12.014","volume":"188","author":"Q Chen","year":"2025","unstructured":"Chen, Q. et al. Systems-level immunomonitoring in children with solid tumors to enable precision medicine. Cell 188, 1425\u20131440.e1411 (2025).","journal-title":"Cell"},{"key":"77358_CR72","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/cyto.a.22271","volume":"83","author":"R Finck","year":"2013","unstructured":"Finck, R. et al. Normalization of mass cytometry data with bead standards. Cytometry A 83, 483\u2013494 (2013).","journal-title":"Cytometry A"},{"key":"77358_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-08986-0","volume":"15","author":"J Abraham","year":"2025","unstructured":"Abraham, J. et al. Validation of an AI-enabled exome\/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. Sci. Rep. 15, 21173 (2025).","journal-title":"Sci. Rep."},{"key":"77358_CR74","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13046-021-02016-3","volume":"40","author":"Y Fujii","year":"2021","unstructured":"Fujii, Y. et al. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. J. Exp. Clin. Cancer Res. 40, 215 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"77358_CR75","doi-asserted-by":"publisher","first-page":"642","DOI":"10.18632\/oncotarget.28761","volume":"16","author":"V Domenyuk","year":"2025","unstructured":"Domenyuk, V. et al. Clinical and analytical validation of MI Cancer Seek(R), a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay. Oncotarget 16, 642\u2013659 (2025).","journal-title":"Oncotarget"},{"key":"77358_CR76","doi-asserted-by":"crossref","unstructured":"Basch, E. et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J. Natl. Cancer Inst. 106, dju244 (2014).","DOI":"10.1093\/jnci\/dju244"}],"updated-by":[{"DOI":"10.1038\/s41467-026-79579-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:00:00Z","timestamp":1794528000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77358-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:02:58Z","timestamp":1794643378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77358-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77358"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77358-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8048398\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-026-79579-2","URL":"https:\/\/doi.org\/10.1038\/s41467-026-79579-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L., G.D.C., L.V.V., A.B., P.K. and T.H. are employees of the study Sponsor (iOnctura) with stock options. R.Z. is an employee of the study Sponsor (iOnctura). A.M.D.G. is an investigator for MSD, Bristol Myers Squibb, Incyte, Pierre Fabre, Novartis, Sun Pharma, Immunocore, Sanofi and Servier and receives consulting fees and\/or speaker fees\/honoraria and\/or research funding from Bristol Myers Squibb, Roche, Sanofi, Pierre Fabre, GlaxoSmithKline and Vyvamed. M.S. sits on advisory boards for Servier, Incyte, GlaxoSmithKline and Bristol Myers Squibb, receives travel grants for Pfizer, Sanofi, Roche, Servier and BeOne and receives consulting fees and\/or speaker fees\/honoraria and\/or research funding from GlaxoSmithKline and Bristol Myers Squibb. P.S. is a speaker for Bristol Myers Squibb, sits on advisory boards for Iovance Biotherapeutics and Sun Pharma, is an investigator for Accession Therapeutics, BioNTech, C4 Therapeutics, Corvus Pharmaceuticals, Ideaya Biosciences, Immunocore, Iovance Biotherapeutics, Microbiotica, Moderna, Mythic and for Eisai. M.V. is an investigator for Novartis. P.B. and T.L. are shareholders and cofounders of Cytodelics AB, which produces and distributes whole blood cell stabiliser solutions used within this study. P.B. is scientific advisor to Pixelgen Technologies AB, Sention Health AB, Helaina Inc., Scailyte AG, and Oxford Immune Algorithmics, holds shares with Pixelgen Technologies, Sention Health, Infinant Health, Single Technologies and AstraZeneca and is a speaker for Nestl\u00e9, Sobi, AstraZeneca, Pfizer and CSL Behring. M.D. is an employee of Fortrea with stock options. A.C. and N.S. are employed by radiomics.bio consultancy with stock options. M.O. receives consulting fees and\/or speaker fees\/honoraria and\/or research funding from radiomics.bio. R.S. is an employee of Astellas. A.A.A. is an employee of BOTh Analytics. A.M., U.P. and G.P. receive consulting fees and\/or speaker fees\/honoraria and\/or research funding from the study sponsor (iOnctura). G.H. and E.W. are employees of Veramed. V.V. and A.L.P. are employees of 4HF Biotec GmbH and have stock options with APEX OncoScience SAS. M.P. and D.S. are employees of Caris Life Sciences with stock options. C.C.S. sits on advisory boards for ADC Therapeutics, Karyopharm Tx, Bristol Myers Squibb, Roche, MSD, Scenic Biotech, Sobi, Abbvie and Genmab and receives consulting fees and\/or speaker fees\/honoraria and\/or research funding from Sanofi, ADC Therapeutics, Bristol Myers Squibb, Incyte, Roche, Janssen Oncology, Takeda, MSD, AstraZeneca and Gilead. A.S. is employed by IRCCS Humanitas Research Hospital, is a speaker for Takeda, Bristol Myers Squibb, Roche, AbbVie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD and Beigene, sits on advisory boards for Bristol Myers Squibb, Servier, Gilead, Pfizer, Eisai, Bayer and MSD and receives consulting fees and\/or speaker fees\/honoraria and\/or research funding from Sanofi and Incyte. T.H.E. receives travel grants from Bristol Myers Squibb, MSD, Pierre Fabre, Eisai, Nucana and Roche and receives consulting fees and\/or speaker fees\/honoraria and\/or research funding from the study sponsor (iOnctura), Karus Therapeutics, Eisai, Bristol Myers Squibb, MSD, United Medical, Nucana, Roche\/Genentech, Ascelia, AstraZeneca, Bicycle Therapeutics, Medivir, Seagen, CV6 Therapeutics, Ewopharma, Beigene, Basilea, Celgene, MiNA Therapeutics, Lilly, Merck Serono, Janssen, Johnson & Johnson, Verastem, Novartis, Iovance Biotherapeutics, Sanofi\/Aventis, Clovis Oncology, Plexxikon, Sierra Pharma, GlaxoSmithKline, Halozyme, CytomX Therapeutics, Vertex, Athenex, Adaptimmune, Immunocore, Modulate Pharma, Berg, Starpharma, BiolineRx, UCB, Sapience Therapeutics, Astellas Pharma, Boehringer Ingelheim, Avacta Life Sciences, Nurix, Codiak BioSciences, T3 Pharmaceuticals, BioNTech, Moderna Therapeutics, Exelixis, Exscientia, Bayer, Amgen, Sotio and Pfizer. M.M. owns stock in Epigen Therapeutics and Theravance, sits on advisory boards for MSD, Roche and Bristol Myers Squibb and receives consulting fees and\/or speaker fees\/honoraria and\/or research funding from the study sponsor (iOnctura), MSD, Roche, Bristol Myers Squibb, Sanofi, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, GlaxoSmithKline, Sciclone, Alfasigma and Merck Serono. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10219"}}